Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Lialda® (mesalamine) – Expanded indication
June 26, 2020 - The FDA approved Takeda’s Lialda (mesalamine), for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.
